tiprankstipranks
Bicara Therapeutics Inc. (BCAX)
NASDAQ:BCAX
US Market
BCAX
Bicara Therapeutics Inc.
RESEARCH TOOLSreports
Want to see BCAX full AI Analyst Report?

Bicara Therapeutics Inc. (BCAX) Stock Forecast & Price Target

82 Followers
See the Price Targets and Ratings of:

BCAX Analyst Ratings

Moderate Buy
11Ratings
Moderate Buy
8 Buy
3 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Bicara
Therapeutics Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BCAX Stock 12 Month Forecast

Average Price Target

$32.55
▲(20.45% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Bicara Therapeutics Inc. in the last 3 months. The average price target is $32.55 with a high forecast of $45.00 and a low forecast of $20.00. The average price target represents a 20.45% change from the last price of $27.02.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","46":"$46","18.25":"$18.25","27.5":"$27.5","36.75":"$36.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.54545454545455,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,18.25,27.5,36.75,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.1,28.47692307692308,29.853846153846156,31.230769230769234,32.60769230769231,33.98461538461539,35.36153846153846,36.738461538461536,38.11538461538461,39.49230769230769,40.86923076923077,42.246153846153845,43.62307692307692,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.1,27.51888111888112,27.93776223776224,28.356643356643357,28.775524475524477,29.194405594405595,29.613286713286715,30.032167832167833,30.451048951048953,30.86993006993007,31.28881118881119,31.70769230769231,32.12657342657343,{"y":32.54545454545455,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.1,26.553846153846155,26.00769230769231,25.461538461538463,24.915384615384617,24.36923076923077,23.823076923076925,23.276923076923076,22.730769230769234,22.184615384615384,21.63846153846154,21.092307692307692,20.546153846153846,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.53,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.33,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.83,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.76,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.59,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.67,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.62,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.91,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.1,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$45.00Average Price Target$32.55Lowest Price Target$20.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BMO Capital Analyst forecast on BCAX
Unknown Analyst
BMO Capital
Not Ranked
BMO Capital
$35
Buy
29.53%
Upside
Initiated
08/18/26
Bicara Therapeutics initiated with an Outperform at BMO CapitalBicara Therapeutics initiated with an Outperform at BMO Capital
Stifel Nicolaus Analyst forecast on BCAX
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$45
Buy
66.54%
Upside
Reiterated
08/13/26
Stifel Nicolaus Remains a Buy on Bicara Therapeutics Inc. (BCAX)
Mizuho Securities Analyst forecast on BCAX
Joseph Catanzaro
Mizuho Securities
Mizuho Securities
$20
Hold
-25.98%
Downside
Reiterated
08/13/26
Mizuho Securities Reaffirms Their Hold Rating on Bicara Therapeutics Inc. (BCAX)
Wedbush Analyst forecast on BCAX
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$33
Buy
22.13%
Upside
Reiterated
08/12/26
Wedbush Reaffirms Their Buy Rating on Bicara Therapeutics Inc. (BCAX)
Wells Fargo Analyst forecast on BCAX
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$16→$23
Hold
-14.88%
Downside
Assigned
08/12/26
Wells Fargo Issues a Hold Rating on Bicara Therapeutics Inc. (BCAX)
BTIG Analyst forecast on BCAX
Jeet Mukherjee
BTIG
BTIG
$28→$39
Buy
44.34%
Upside
Reiterated
08/12/26
Analysts Offer Insights on NA Companies: Enhanced Group (NYSE: ENHA), MNTN, Inc Class A (NYSE: MNTN) and Bicara Therapeutics Inc. (NASDAQ: BCAX)
Morgan Stanley Analyst forecast on BCAX
Judah Frommer
Morgan Stanley
Morgan Stanley
$39→$37
Buy
36.94%
Upside
Reiterated
08/12/26
Analysts Have Conflicting Sentiments on These NA Companies: Bending Spoons (NASDAQ: BSP), eToro (NASDAQ: ETOR) and Bicara Therapeutics Inc. (NASDAQ: BCAX)
JonesTrading Analyst forecast on BCAX
Boris Peaker
JonesTrading
JonesTrading
$30
Buy
11.03%
Upside
Reiterated
08/11/26
Analysts Are Bullish on Top NA Stocks: Veradermics, Incorporated (MANE), Bicara Therapeutics Inc. (BCAX)
Bank of America Securities Analyst forecast on BCAX
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$34
Buy
25.83%
Upside
Reiterated
08/11/26
Analysts Offer Insights on NA Companies: Smithfield Foods (NASDAQ: SFD), Bicara Therapeutics Inc. (NASDAQ: BCAX) and Concentra Group Holdings Parent, Inc. (NYSE: CON)
Goldman Sachs Analyst forecast on BCAX
Rajan Sharma
Goldman Sachs
Goldman Sachs
$18→$20
Hold
-25.98%
Downside
Assigned
08/11/26
Analysts Conflicted on These NA Names: Bicara Therapeutics Inc. (NASDAQ: BCAX), CoreWeave (NASDAQ: CRWV) and Cardinal Infrastructure Group, Inc. (NASDAQ: CDNL)
H.C. Wainwright Analyst forecast on BCAX
Robert Burns
H.C. Wainwright
H.C. Wainwright
$42
Buy
55.44%
Upside
Reiterated
06/01/26
Analyst Reiterates Buy on Bicara, Keeps 12-Month Price Target Unchanged at $42 on Encouraging Ficerafusp Alfa Data
Guggenheim Analyst forecast on BCAX
Bradley Canino
Guggenheim
Guggenheim
$42
Buy
55.44%
Upside
Reiterated
05/26/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (NASDAQ: BCAX), Abivax SA Sponsored ADR (NASDAQ: ABVX) and Arcutis Biotherapeutics (NASDAQ: ARQT)
TD Cowen Analyst forecast on BCAX
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/11/26
Tyler Van Buren Reiterates Buy Rating on Ficera, Citing Strong Phase III Momentum and Best-in-Class Potential in HPV-Negative Head and Neck Cancer
Citizens JMP Analyst forecast on BCAX
Reni Benjamin
Citizens JMP
Citizens JMP
$31
Buy
14.73%
Upside
Initiated
01/29/26
Bicara Therapeutics initiated with an Outperform at CitizensBicara Therapeutics initiated with an Outperform at Citizens
Piper Sandler Analyst forecast on BCAX
Kelsey Goodwin
Piper Sandler
Piper Sandler
$36
Buy
33.23%
Upside
Reiterated
12/08/25
Piper Sandler Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BMO Capital Analyst forecast on BCAX
Unknown Analyst
BMO Capital
Not Ranked
BMO Capital
$35
Buy
29.53%
Upside
Initiated
08/18/26
Bicara Therapeutics initiated with an Outperform at BMO CapitalBicara Therapeutics initiated with an Outperform at BMO Capital
Stifel Nicolaus Analyst forecast on BCAX
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$45
Buy
66.54%
Upside
Reiterated
08/13/26
Stifel Nicolaus Remains a Buy on Bicara Therapeutics Inc. (BCAX)
Mizuho Securities Analyst forecast on BCAX
Joseph Catanzaro
Mizuho Securities
Mizuho Securities
$20
Hold
-25.98%
Downside
Reiterated
08/13/26
Mizuho Securities Reaffirms Their Hold Rating on Bicara Therapeutics Inc. (BCAX)
Wedbush Analyst forecast on BCAX
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$33
Buy
22.13%
Upside
Reiterated
08/12/26
Wedbush Reaffirms Their Buy Rating on Bicara Therapeutics Inc. (BCAX)
Wells Fargo Analyst forecast on BCAX
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$16→$23
Hold
-14.88%
Downside
Assigned
08/12/26
Wells Fargo Issues a Hold Rating on Bicara Therapeutics Inc. (BCAX)
BTIG Analyst forecast on BCAX
Jeet Mukherjee
BTIG
BTIG
$28→$39
Buy
44.34%
Upside
Reiterated
08/12/26
Analysts Offer Insights on NA Companies: Enhanced Group (NYSE: ENHA), MNTN, Inc Class A (NYSE: MNTN) and Bicara Therapeutics Inc. (NASDAQ: BCAX)
Morgan Stanley Analyst forecast on BCAX
Judah Frommer
Morgan Stanley
Morgan Stanley
$39→$37
Buy
36.94%
Upside
Reiterated
08/12/26
Analysts Have Conflicting Sentiments on These NA Companies: Bending Spoons (NASDAQ: BSP), eToro (NASDAQ: ETOR) and Bicara Therapeutics Inc. (NASDAQ: BCAX)
JonesTrading Analyst forecast on BCAX
Boris Peaker
JonesTrading
JonesTrading
$30
Buy
11.03%
Upside
Reiterated
08/11/26
Analysts Are Bullish on Top NA Stocks: Veradermics, Incorporated (MANE), Bicara Therapeutics Inc. (BCAX)
Bank of America Securities Analyst forecast on BCAX
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$34
Buy
25.83%
Upside
Reiterated
08/11/26
Analysts Offer Insights on NA Companies: Smithfield Foods (NASDAQ: SFD), Bicara Therapeutics Inc. (NASDAQ: BCAX) and Concentra Group Holdings Parent, Inc. (NYSE: CON)
Goldman Sachs Analyst forecast on BCAX
Rajan Sharma
Goldman Sachs
Goldman Sachs
$18→$20
Hold
-25.98%
Downside
Assigned
08/11/26
Analysts Conflicted on These NA Names: Bicara Therapeutics Inc. (NASDAQ: BCAX), CoreWeave (NASDAQ: CRWV) and Cardinal Infrastructure Group, Inc. (NASDAQ: CDNL)
H.C. Wainwright Analyst forecast on BCAX
Robert Burns
H.C. Wainwright
H.C. Wainwright
$42
Buy
55.44%
Upside
Reiterated
06/01/26
Analyst Reiterates Buy on Bicara, Keeps 12-Month Price Target Unchanged at $42 on Encouraging Ficerafusp Alfa Data
Guggenheim Analyst forecast on BCAX
Bradley Canino
Guggenheim
Guggenheim
$42
Buy
55.44%
Upside
Reiterated
05/26/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (NASDAQ: BCAX), Abivax SA Sponsored ADR (NASDAQ: ABVX) and Arcutis Biotherapeutics (NASDAQ: ARQT)
TD Cowen Analyst forecast on BCAX
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/11/26
Tyler Van Buren Reiterates Buy Rating on Ficera, Citing Strong Phase III Momentum and Best-in-Class Potential in HPV-Negative Head and Neck Cancer
Citizens JMP Analyst forecast on BCAX
Reni Benjamin
Citizens JMP
Citizens JMP
$31
Buy
14.73%
Upside
Initiated
01/29/26
Bicara Therapeutics initiated with an Outperform at CitizensBicara Therapeutics initiated with an Outperform at Citizens
Piper Sandler Analyst forecast on BCAX
Kelsey Goodwin
Piper Sandler
Piper Sandler
$36
Buy
33.23%
Upside
Reiterated
12/08/25
Piper Sandler Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bicara Therapeutics Inc.

3 Months
Robert BurnsH.C. Wainwright
Success Rate
9/13 ratings generated profit
69%
Average Return
+15.62%
Copying Robert Burns's trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +15.62% per trade.
1 Year
Robert BurnsH.C. Wainwright
Success Rate
12/13 ratings generated profit
92%
Average Return
+52.08%
Copying Robert Burns's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +52.08% per trade.
2 Years
Robert BurnsH.C. Wainwright
Success Rate
13/13 ratings generated profit
100%
Average Return
+64.48%
Copying Robert Burns's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +64.48% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BCAX Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
8
9
6
6
4
Buy
3
10
9
9
6
Hold
3
4
5
4
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
23
20
19
15
In the current month, BCAX has received 10 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. BCAX average Analyst price target in the past 3 months is 32.55.
Each month's total comprises the sum of three months' worth of ratings.

BCAX Financial Forecast

BCAX Earnings Forecast

Next quarter’s earnings estimate for BCAX is -$0.81 with a range of -$0.97 to -$0.42. The previous quarter’s EPS was -$0.82. BCAX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year BCAX has Performed in-line its overall industry.
Next quarter’s earnings estimate for BCAX is -$0.81 with a range of -$0.97 to -$0.42. The previous quarter’s EPS was -$0.82. BCAX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year BCAX has Performed in-line its overall industry.
No data currently available

BCAX Sales Forecast

Next quarter’s sales forecast for BCAX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. BCAX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year BCAX has Performed in-line its overall industry.
Next quarter’s sales forecast for BCAX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. BCAX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year BCAX has Performed in-line its overall industry.

BCAX Stock Forecast FAQ

What is BCAX’s average 12-month price target, according to analysts?
Based on analyst ratings, Bicara Therapeutics Inc.’s 12-month average price target is 32.55.
    What is BCAX’s upside potential, based on the analysts’ average price target?
    Bicara Therapeutics Inc. has 20.45% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BCAX a Buy, Sell or Hold?
          Bicara Therapeutics Inc. has a consensus rating of Moderate Buy which is based on 8 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Bicara Therapeutics Inc.’s price target?
            The average price target for Bicara Therapeutics Inc. is 32.55. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $45.00 ,the lowest forecast is $20.00. The average price target represents 20.45% Increase from the current price of $27.02.
              What do analysts say about Bicara Therapeutics Inc.?
              Bicara Therapeutics Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of BCAX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.